Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Viridian Therapeutics (VRDN – Research Report) today and set a price ...

Leerink Partners analyst Thomas Smith has maintained their bullish stance on VRDN stock, giving a Buy rating on January 14.Invest with ...

Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Free Report) has earned an average recommendation of “Moderate Buy” from the twelve research firms that are currently covering the company, Ratings ...

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that ...

Trading Advice for Viridian Therapeutics Inc. VRDN including day trading swing trading and long term investing plans for VRDN ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

VRDN Viridian Therapeutics Inc Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease - Veligrotug, ...

WALTHAM, Mass., February 06, 2025--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines ...

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a ...